Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 58.17

+3.9%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (9602)	12/3/2003 6:32:54 PM
From: Madharry	Read Replies (1) of 52153

Its interesting to me that there has not been one comment on this thread about the effect of the merck deal on the shares of neurogen. in the premarket after the deal was announced the stock was about 8.60 a +2 increase, the high was 11.80 or so and the close was around 10.70. today the stock closed at 8.95 after being as low as 8.60. Does anyone here have any thoughts as to how much added value to the market cap the merck deal should bring? I felt the way i look at things the immediate impact was in the $60MM- $100MM range and this not taking into account the added value of Merck respecting the technology enough to buy into it. As a result i currently own a full position in Neurogen.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next